VCIM
KPTI icon

Velan Capital Investment Management’s Karyopharm Therapeutics KPTI Stock Holding History

Velan Capital Investment Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$83.5K Buy
+15,000
New +$114K 0.05% 47
2025
Q1 		– Sell
-2,667
Closed -$27.1K – 53
2024
Q4 		$27.1K Buy
+2,667
New +$32.2K 0.02% 41

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Velan Capital Investment Management's KPTI Position: Q1 2026 in Review

Velan Capital Investment Management opened a new position in Karyopharm Therapeutics (KPTI) in Q1 2026: 15,000 shares worth $83.5K. The stake represents 0.05% of the portfolio and ranks #47 among its holdings. This is a return to the name: Velan Capital Investment Management previously reported a position in KPTI as recently as Q4 2024.

Velan Capital Investment Management first reported a position in KPTI in Q4 2024 and has held it in 2 quarters since. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Velan Capital Investment Management held 15,000 shares of Karyopharm Therapeutics worth $83.5K as of Q1 2026.
  • Karyopharm Therapeutics was a new Velan Capital Investment Management position in Q1 2026.
  • Karyopharm Therapeutics made up 0.05% of Velan Capital Investment Management's portfolio in Q1 2026, its #47 holding.
  • Velan Capital Investment Management first reported a position in Karyopharm Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Velan Capital Investment Management's 13F filing for Q1 2026, filed 15 May 2026.